The fate of anti-HLA antibodies following liver transplantation

被引:0
作者
Norman, Douglas J. [1 ,2 ]
Enestvedt, C. Kristian [3 ]
Naugler, Willscott E. [4 ]
Erhan, Rouella [1 ]
Shaut, Carley A. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Lab Immunogenet & Transplantat, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, Sect Transplantat Med, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Dept Surg, Div Abdominal Organ Transplantat, Portland, OR USA
[4] Oregon Hlth & Sci Univ, Dept Med, Div Gastroenterol & Hepatol, Portland, OR USA
来源
FRONTIERS IN NEPHROLOGY | 2024年 / 4卷
关键词
liver transplant; anti HLA antibodies; donor specific antibodies; HLA class I and class II typing; liver graft survival; DONOR-SPECIFIC ANTIBODIES; MEDIATED REJECTION; CLASS-I; IMPACT; ALLOANTIBODIES; ASSOCIATION; EXPRESSION; RECIPIENTS; SURVIVAL; OUTCOMES;
D O I
10.3389/fneph.2024.1403096
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction Liver transplant recipients may have pre-formed anti-HLA antibodies directed to mismatched HLA of the liver donor (donor specific antibodies, DSA) or not directed to the liver donor (non-donor specific, non-DSA). We observed the fate of these antibodies (DSA and non-DSA) at 12 months after transplant.Methods Patients transplanted between 4/2015 and 12/2018 (N = 216) who had anti-HLA antibody measurements at both transplant and 12 months posttransplant (N = 124) and with DSAs at transplant (N = 31) were considered informative for a paired analysis of the natural history of DSA and non-DSA following liver transplantation.Results Class I DSAs and non-DSAs decreased between transplant and 12 months; however, Class I DSAs essentially disappeared by 12 months while Class I non-DSAs did not. Anti-HLA Class II DSAs performed differently. While there was a significant drop in values between transplant and 12 months, these antibodies mostly persisted at a low level.Discussion Our study demonstrated a significant difference in the kinetics of DSA compared to non-DSA following liver transplantation, most profoundly for anti-HLA Class I antibodies. Class I DSAs were mostly absent at 12 months while Class II DSAs persisted, although at lower levels. The mechanisms of reduction in anti-HLA antibodies following liver transplantation are not completely understood and were not pursued as a part of this study. This detailed analysis of Class I and Class II DSAs and non-DSAs represents and important study to explore the change in antibodies at one year from liver transplantation.
引用
收藏
页数:9
相关论文
共 46 条
[1]   Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility [J].
Castillo-Rama, Marcela ;
Castro, Maria Jose ;
Bernardo, Ivan ;
Meneu-Diaz, Juan Carlos ;
Elola-Olaso, Almudena Moreno ;
Calleja-Antolin, Sara M. ;
Romo, Eva ;
Morales, Pablo ;
Moreno, Enrique ;
Paz-Artal, Estela .
LIVER TRANSPLANTATION, 2008, 14 (04) :554-562
[2]   The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives [J].
Cheng, Elaine Y. .
JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
[3]   Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect on Long-Term Graft Survival [J].
Ciszek, Michal ;
Foroncewicz, Bartosz ;
Mucha, Krzysztof ;
Zochowska, Dorota ;
Ziarkiewicz-Wroblewska, Bogna ;
Krawczyk, Marek ;
Paczek, Leszek .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013,
[4]   Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation [J].
Couchonnal, Eduardo ;
Rivet, Christine ;
Ducreux, Stephanie ;
Dumortier, Jerome ;
Bosch, Alexie ;
Boillot, Olivier ;
Collardeau-Frachon, Sophie ;
Dubois, Remi ;
Hervieu, Valerie ;
Andre, Patrice ;
Scoazec, Jean-Yves ;
Lachaux, Alain ;
Dubois, Valerie ;
Guillaud, Olivier .
TRANSPLANT IMMUNOLOGY, 2017, 45 :8-14
[5]   Donor-Directed MHC Class I Antibody Is Preferentially Cleared from Sensitized Recipients of Combined Liver/Kidney Transplants [J].
Dar, W. ;
Agarwal, A. ;
Watkins, C. ;
Gebel, H. M. ;
Bray, R. A. ;
Kokko, K. E. ;
Pearson, T. C. ;
Knechtle, S. J. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (04) :841-847
[6]   De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients [J].
Del Bello, Arnaud ;
Congy-Jolivet, Nicolas ;
Danjoux, Marie ;
Muscari, Fabrice ;
Lavayssiere, Laurence ;
Esposito, Laure ;
Cardeau-Desangles, Isabelle ;
Guitard, Joelle ;
Dorr, Gaelle ;
Milongo, David ;
Suc, Bertrand ;
Duffas, Jean Pierre ;
Alric, Laurent ;
Bureau, Christophe ;
Guilbeau-Frugier, Celine ;
Rostaing, Lionel ;
Kamar, Nassim .
TRANSPLANT INTERNATIONAL, 2015, 28 (12) :1371-1382
[7]   ABO-compatible liver allograft antibody-mediated rejection: an update [J].
Demetris, Anthony J. ;
Zeevi, Adriana ;
O'Leary, Jacqueline G. .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2015, 20 (03) :314-324
[8]   Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation [J].
den Dulk, Anne Claire ;
Shi, Xiaolei ;
Verhoeven, Cornelia. J. ;
Dubbeld, Jeroen ;
Claas, Frans H. J. ;
Wolterbeek, Ron ;
Brand-Schaaf, Simone H. ;
Verspaget, Hein W. ;
Sarasqueta, Arantza Farina ;
van der Laan, Luc J. W. ;
Metselaar, Herold J. ;
van Hoek, Bart ;
Kwekkeboom, Jaap ;
Roelen, Dave L. .
CLINICAL TRANSPLANTATION, 2018, 32 (02)
[9]  
Donaldson PT., 1995, Assess by cytotoxic Flow cytom Transplant, V60, P1016, DOI [10.1097/00007890-199511000-00024, DOI 10.1097/00007890-199511000-00024]
[10]  
Everly Matthew J, 2014, Clin Transpl, P125